MX2008013911A - Uso de escitalopram para mejorar la capacidad de conocimiento. - Google Patents
Uso de escitalopram para mejorar la capacidad de conocimiento.Info
- Publication number
- MX2008013911A MX2008013911A MX2008013911A MX2008013911A MX2008013911A MX 2008013911 A MX2008013911 A MX 2008013911A MX 2008013911 A MX2008013911 A MX 2008013911A MX 2008013911 A MX2008013911 A MX 2008013911A MX 2008013911 A MX2008013911 A MX 2008013911A
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- use according
- escitalopram
- day
- disease
- Prior art date
Links
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 title claims abstract description 69
- 229960004341 escitalopram Drugs 0.000 title claims abstract description 67
- 230000019771 cognition Effects 0.000 claims abstract description 48
- 239000003814 drug Substances 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 230000003292 diminished effect Effects 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 109
- 238000011282 treatment Methods 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- -1 lloperidone Chemical compound 0.000 claims description 21
- 206010012289 Dementia Diseases 0.000 claims description 18
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 17
- 201000000980 schizophrenia Diseases 0.000 claims description 13
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 12
- 230000015654 memory Effects 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 208000019901 Anxiety disease Diseases 0.000 claims description 11
- 230000000561 anti-psychotic effect Effects 0.000 claims description 11
- 229960001534 risperidone Drugs 0.000 claims description 11
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 11
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 10
- 239000000164 antipsychotic agent Substances 0.000 claims description 10
- 230000006866 deterioration Effects 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 10
- WEIMMECSAQVSGO-UHFFFAOYSA-N n-(3-hydroxy-4-propylphenyl)acetamide Chemical compound CCCC1=CC=C(NC(C)=O)C=C1O WEIMMECSAQVSGO-UHFFFAOYSA-N 0.000 claims description 10
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 9
- 229940049706 benzodiazepine Drugs 0.000 claims description 9
- 150000001557 benzodiazepines Chemical class 0.000 claims description 9
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 9
- 208000030507 AIDS Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 208000024714 major depressive disease Diseases 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 229960004170 clozapine Drugs 0.000 claims description 7
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 7
- 229960005017 olanzapine Drugs 0.000 claims description 7
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 7
- 229960004431 quetiapine Drugs 0.000 claims description 7
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 7
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960000652 sertindole Drugs 0.000 claims description 7
- BABFYCSPNDKXRI-UHFFFAOYSA-N 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl 4-aminobutanoate Chemical compound C1CN(CCOC(=O)CCCN)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 BABFYCSPNDKXRI-UHFFFAOYSA-N 0.000 claims description 6
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 6
- CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 claims description 6
- ZZQNEJILGNNOEP-UHFFFAOYSA-N Ocaperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)C=CC=C4C)=NOC2=C1 ZZQNEJILGNNOEP-UHFFFAOYSA-N 0.000 claims description 6
- 229950009087 bifeprunox Drugs 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 229960001432 lurasidone Drugs 0.000 claims description 6
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 claims description 6
- 229950010634 ocaperidone Drugs 0.000 claims description 6
- 229960001057 paliperidone Drugs 0.000 claims description 6
- 238000001671 psychotherapy Methods 0.000 claims description 6
- 229960000607 ziprasidone Drugs 0.000 claims description 6
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 6
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 claims description 5
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 claims description 5
- PXUIZULXJVRBPC-UHFFFAOYSA-N 1'-[3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]hexahydro-2H-spiro[imidazo[1,2-a]pyridine-3,4'-piperidin]-2-one Chemical compound C12=CC(Cl)=CC=C2CCC2=CC=CC=C2N1CCCN1CCC2(C(NC3CCCCN32)=O)CC1 PXUIZULXJVRBPC-UHFFFAOYSA-N 0.000 claims description 5
- DKMFBWQBDIGMHM-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-1-butanone Chemical compound C1CC(C)CCN1CCCC(=O)C1=CC=C(F)C=C1 DKMFBWQBDIGMHM-UHFFFAOYSA-N 0.000 claims description 5
- MDLAAYDRRZXJIF-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol Chemical compound C1CC(O)(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 MDLAAYDRRZXJIF-UHFFFAOYSA-N 0.000 claims description 5
- WFPIAZLQTJBIFN-BLLMUTORSA-N 2-[4-[(3e)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol Chemical compound C1CN(CCO)CCN1CC\C=C/1C2=CC(Cl)=CC=C2SC2=CC=CC=C2\1 WFPIAZLQTJBIFN-BLLMUTORSA-N 0.000 claims description 5
- FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 claims description 5
- BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 claims description 5
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 5
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 claims description 5
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 claims description 5
- KAAZGXDPUNNEFN-UHFFFAOYSA-N Clotiapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2SC2=CC=C(Cl)C=C12 KAAZGXDPUNNEFN-UHFFFAOYSA-N 0.000 claims description 5
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 5
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 claims description 5
- JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 claims description 5
- JNNOSTQEZICQQP-UHFFFAOYSA-N N-desmethylclozapine Chemical compound N=1C2=CC(Cl)=CC=C2NC2=CC=CC=C2C=1N1CCNCC1 JNNOSTQEZICQQP-UHFFFAOYSA-N 0.000 claims description 5
- XCWPUUGSGHNIDZ-UHFFFAOYSA-N Oxypertine Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C)=C1CCN(CC1)CCN1C1=CC=CC=C1 XCWPUUGSGHNIDZ-UHFFFAOYSA-N 0.000 claims description 5
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 5
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 claims description 5
- 208000028017 Psychotic disease Diseases 0.000 claims description 5
- UNRHXEPDKXPRTM-UHFFFAOYSA-N Sultopride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=CC=C1OC UNRHXEPDKXPRTM-UHFFFAOYSA-N 0.000 claims description 5
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 5
- 229960005054 acepromazine Drugs 0.000 claims description 5
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 claims description 5
- 101150109352 acr-16 gene Proteins 0.000 claims description 5
- 229960003036 amisulpride Drugs 0.000 claims description 5
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims description 5
- 229960004372 aripiprazole Drugs 0.000 claims description 5
- 229960005245 asenapine Drugs 0.000 claims description 5
- 229960002507 benperidol Drugs 0.000 claims description 5
- 229950002871 blonanserin Drugs 0.000 claims description 5
- 229960004037 bromperidol Drugs 0.000 claims description 5
- 229960000608 butaperazine Drugs 0.000 claims description 5
- DVLBYTMYSMAKHP-UHFFFAOYSA-N butaperazine Chemical compound C12=CC(C(=O)CCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 DVLBYTMYSMAKHP-UHFFFAOYSA-N 0.000 claims description 5
- 229960005123 cariprazine Drugs 0.000 claims description 5
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 claims description 5
- 229960001076 chlorpromazine Drugs 0.000 claims description 5
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 5
- 229960001552 chlorprothixene Drugs 0.000 claims description 5
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 claims description 5
- 229960000394 droperidol Drugs 0.000 claims description 5
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims description 5
- 229960005220 fluanisone Drugs 0.000 claims description 5
- IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 claims description 5
- 229960002419 flupentixol Drugs 0.000 claims description 5
- 229960003878 haloperidol Drugs 0.000 claims description 5
- 229960004145 levosulpiride Drugs 0.000 claims description 5
- 229960000423 loxapine Drugs 0.000 claims description 5
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims description 5
- 229960001861 melperone Drugs 0.000 claims description 5
- 229960000300 mesoridazine Drugs 0.000 claims description 5
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 claims description 5
- 229940042053 methotrimeprazine Drugs 0.000 claims description 5
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 claims description 5
- 229960004938 molindone Drugs 0.000 claims description 5
- 229960000758 moperone Drugs 0.000 claims description 5
- AGAHNABIDCTLHW-UHFFFAOYSA-N moperone Chemical compound C1=CC(C)=CC=C1C1(O)CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 AGAHNABIDCTLHW-UHFFFAOYSA-N 0.000 claims description 5
- 229960003894 mosapramine Drugs 0.000 claims description 5
- 229960004505 penfluridol Drugs 0.000 claims description 5
- 229960002195 perazine Drugs 0.000 claims description 5
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 claims description 5
- 229960000769 periciazine Drugs 0.000 claims description 5
- LUALIOATIOESLM-UHFFFAOYSA-N periciazine Chemical compound C1CC(O)CCN1CCCN1C2=CC(C#N)=CC=C2SC2=CC=CC=C21 LUALIOATIOESLM-UHFFFAOYSA-N 0.000 claims description 5
- 229960000762 perphenazine Drugs 0.000 claims description 5
- 229960003634 pimozide Drugs 0.000 claims description 5
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 5
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 claims description 5
- 229960003252 pipotiazine Drugs 0.000 claims description 5
- JOMHSQGEWSNUKU-UHFFFAOYSA-N pipotiazine Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 JOMHSQGEWSNUKU-UHFFFAOYSA-N 0.000 claims description 5
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 claims description 5
- 229960003111 prochlorperazine Drugs 0.000 claims description 5
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims description 5
- 229960003598 promazine Drugs 0.000 claims description 5
- 229960004940 sulpiride Drugs 0.000 claims description 5
- 229960004724 sultopride Drugs 0.000 claims description 5
- 229950011332 talnetant Drugs 0.000 claims description 5
- 229960004728 thiopropazate Drugs 0.000 claims description 5
- AIUHRQHVWSUTGJ-UHFFFAOYSA-N thiopropazate Chemical compound C1CN(CCOC(=O)C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 AIUHRQHVWSUTGJ-UHFFFAOYSA-N 0.000 claims description 5
- 229960003397 thioproperazine Drugs 0.000 claims description 5
- VZYCZNZBPPHOFY-UHFFFAOYSA-N thioproperazine Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 VZYCZNZBPPHOFY-UHFFFAOYSA-N 0.000 claims description 5
- 229960002784 thioridazine Drugs 0.000 claims description 5
- 229960005344 tiapride Drugs 0.000 claims description 5
- 229960002324 trifluoperazine Drugs 0.000 claims description 5
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims description 5
- 229960003904 triflupromazine Drugs 0.000 claims description 5
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 claims description 5
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 claims description 5
- 229960004141 zuclopenthixol Drugs 0.000 claims description 5
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 claims description 5
- GUJRSXAPGDDABA-NSHDSACASA-N 3-bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC GUJRSXAPGDDABA-NSHDSACASA-N 0.000 claims description 4
- QOYHHIBFXOOADH-UHFFFAOYSA-N 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 QOYHHIBFXOOADH-UHFFFAOYSA-N 0.000 claims description 4
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims description 4
- 229960000276 acetophenazine Drugs 0.000 claims description 4
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 claims description 4
- 229960003864 clotiapine Drugs 0.000 claims description 4
- 229960003532 fluspirilene Drugs 0.000 claims description 4
- 229960002776 pipamperone Drugs 0.000 claims description 4
- 229960002341 trifluperidol Drugs 0.000 claims description 4
- GPMXUUPHFNMNDH-UHFFFAOYSA-N trifluperidol Chemical compound C1CC(O)(C=2C=C(C=CC=2)C(F)(F)F)CCN1CCCC(=O)C1=CC=C(F)C=C1 GPMXUUPHFNMNDH-UHFFFAOYSA-N 0.000 claims description 4
- RYJXBGGBZJGVQF-UHFFFAOYSA-N veralipride Chemical compound COC1=CC(S(N)(=O)=O)=CC(C(=O)NCC2N(CCC2)CC=C)=C1OC RYJXBGGBZJGVQF-UHFFFAOYSA-N 0.000 claims description 4
- 229960004496 zotepine Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000009225 cognitive behavioral therapy Methods 0.000 claims description 3
- 230000001976 improved effect Effects 0.000 claims description 3
- 229960003030 chlorproethazine Drugs 0.000 claims description 2
- DBOUGBAQLIXZLV-UHFFFAOYSA-N chlorproethazine Chemical compound C1=C(Cl)C=C2N(CCCN(CC)CC)C3=CC=CC=C3SC2=C1 DBOUGBAQLIXZLV-UHFFFAOYSA-N 0.000 claims description 2
- 229960004278 cyamemazine Drugs 0.000 claims description 2
- SLFGIOIONGJGRT-UHFFFAOYSA-N cyamemazine Chemical compound C1=C(C#N)C=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 SLFGIOIONGJGRT-UHFFFAOYSA-N 0.000 claims description 2
- 229960005146 dixyrazine Drugs 0.000 claims description 2
- MSYUMPGNGDNTIQ-UHFFFAOYSA-N dixyrazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC(C)CN1CCN(CCOCCO)CC1 MSYUMPGNGDNTIQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002690 fluphenazine Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229960003448 remoxipride Drugs 0.000 claims description 2
- 229960001968 veralipride Drugs 0.000 claims 2
- 208000018639 Parkinson disease 20 Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 description 31
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 26
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 20
- 229960001653 citalopram Drugs 0.000 description 19
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 15
- 238000010304 firing Methods 0.000 description 15
- 210000004515 ventral tegmental area Anatomy 0.000 description 15
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 12
- 229960003638 dopamine Drugs 0.000 description 10
- 229960003770 reboxetine Drugs 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229940127236 atypical antipsychotics Drugs 0.000 description 7
- 239000003693 atypical antipsychotic agent Substances 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 239000002360 explosive Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000013016 learning Effects 0.000 description 6
- 230000008033 biological extinction Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000002763 pyramidal cell Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 210000002442 prefrontal cortex Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000009172 bursting Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 3
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000011597 CGF1 Diseases 0.000 description 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 2
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000005388 borosilicate glass Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 210000004002 dopaminergic cell Anatomy 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 229940075057 doral Drugs 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
- 230000004793 poor memory Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000002360 prefrontal effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 230000004039 social cognition Effects 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000007497 verbal memory Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 1
- GOTMKOSCLKVOGG-OAHLLOKOSA-N (5R)-8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1([C@@H]2C3=CC(O)=C(Cl)C=C3CCN(C2)C)=CC=CC=C1 GOTMKOSCLKVOGG-OAHLLOKOSA-N 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 102000004076 Dopamine D1 Receptors Human genes 0.000 description 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 description 1
- 229940123100 Dopamine D1 receptor antagonist Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003496 anti-amnesic effect Effects 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- BPHHNXJPFPEJOF-UHFFFAOYSA-J chembl296966 Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC(S([O-])(=O)=O)=C(N)C2=C(O)C(N=NC3=CC=C(C=C3OC)C=3C=C(C(=CC=3)N=NC=3C(=C4C(N)=C(C=C(C4=CC=3)S([O-])(=O)=O)S([O-])(=O)=O)O)OC)=CC=C21 BPHHNXJPFPEJOF-UHFFFAOYSA-J 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000002475 cognitive enhancer Substances 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000000433 dopamine 1 receptor blocking agent Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229960005086 escitalopram oxalate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000007593 synaptic transmission, glutaminergic Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- 229950010357 tetrodotoxin Drugs 0.000 description 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200600621 | 2006-05-02 | ||
| PCT/DK2007/050050 WO2007124757A2 (fr) | 2006-05-02 | 2007-04-30 | Nouvelles applications de l'escitalopram |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008013911A true MX2008013911A (es) | 2008-11-12 |
Family
ID=38134951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008013911A MX2008013911A (es) | 2006-05-02 | 2007-04-30 | Uso de escitalopram para mejorar la capacidad de conocimiento. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2026793A2 (fr) |
| JP (1) | JP2009535367A (fr) |
| KR (1) | KR20090009820A (fr) |
| CN (1) | CN101426494A (fr) |
| AR (1) | AR060732A1 (fr) |
| AU (1) | AU2007245983A1 (fr) |
| BR (1) | BRPI0710230A2 (fr) |
| CA (1) | CA2651002A1 (fr) |
| EA (1) | EA200870491A1 (fr) |
| IL (1) | IL194628A0 (fr) |
| MX (1) | MX2008013911A (fr) |
| NO (1) | NO20085009L (fr) |
| TW (1) | TW200812993A (fr) |
| WO (1) | WO2007124757A2 (fr) |
| ZA (1) | ZA200808632B (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1535616B1 (fr) | 2002-08-22 | 2009-05-13 | Dainippon Sumitomo Pharma Co., Ltd. | Medicament destine au syndrome de la dysfonction d'integration |
| KR101113630B1 (ko) | 2003-06-23 | 2012-02-13 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 노인성 치매 치료제 |
| US20070160537A1 (en) | 2004-02-20 | 2007-07-12 | Takeo Ishiyama | In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia |
| US20090036468A1 (en) * | 2007-08-03 | 2009-02-05 | Forest Laboratories Holdings Limited | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands |
| EP2236138A1 (fr) * | 2009-03-30 | 2010-10-06 | PharmaNeuroBoost N.V. | Pipampèrone faible dose pour le traitement des troubles de l`anxiété et de l`humeur |
| US8258139B2 (en) * | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
| EP3069718A1 (fr) * | 2015-03-17 | 2016-09-21 | Universidade do Minho | Citalopram ou escitalopram destinés à être utilisés dans le traitement de maladies neurodégénératives |
| CN115813888A (zh) | 2016-12-20 | 2023-03-21 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
| EP3558276B1 (fr) | 2016-12-20 | 2024-11-06 | LTS Lohmann Therapie-Systeme AG | Système thérapeutique transdermique contenant de l'asénapine et du polysiloxane ou du polyisobutylène |
| WO2019002204A1 (fr) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | Système thérapeutique transdermique contenant de l'asénapine et un polymère hybride acrylique de type silicone |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| KR102051624B1 (ko) * | 2018-11-30 | 2019-12-02 | 아밀로이드솔루션 주식회사 | 트리플루프로마진 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 퇴행성 뇌질환 치료용 약학 조성물 |
| CN109464436A (zh) * | 2019-01-10 | 2019-03-15 | 高智玉 | 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK213290D0 (da) * | 1990-09-06 | 1990-09-06 | Lundbeck & Co As H | Treatment of cerebrovascular disorders |
| SE9803157D0 (sv) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
| SE9803158D0 (sv) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| ATE329620T1 (de) * | 2000-12-01 | 2006-07-15 | Be Able Llc | Verhaltenchemotherapie |
| WO2002076461A1 (fr) * | 2001-03-26 | 2002-10-03 | Serdar Murat Dursun | Combinaison de reboxetine et de citalopram |
| WO2002087566A1 (fr) * | 2001-05-01 | 2002-11-07 | H. Lundbeck A/S | Utilisation d'escitalopram pur enantiomere |
| US20050014848A1 (en) * | 2002-01-23 | 2005-01-20 | Pfizer Inc. | Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors |
| CA2529857A1 (fr) * | 2002-07-30 | 2004-02-05 | Peter Migaly | Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques |
| AU2003287919B2 (en) * | 2002-12-23 | 2009-11-12 | H. Lundbeck A/S | Escitalopram hydrobromide and a method for the preparation thereof |
| WO2005023243A1 (fr) * | 2003-09-04 | 2005-03-17 | H. Lundbeck A/S | Combinaison d'un inhibiteur de recaptage de serotonine et de loxapine |
| JP2009511607A (ja) * | 2005-10-14 | 2009-03-19 | ハー・ルンドベック・アクチエゼルスカベット | エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤 |
| EA200801081A1 (ru) * | 2005-10-14 | 2008-10-30 | Х. Лундбекк А/С | Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона |
| US20070134322A1 (en) * | 2005-12-14 | 2007-06-14 | Forest Laboratories, Inc. | Modified and pulsatile release pharmaceutical formulations of escitalopram |
-
2007
- 2007-04-25 TW TW096114520A patent/TW200812993A/zh unknown
- 2007-04-30 KR KR1020087025797A patent/KR20090009820A/ko not_active Withdrawn
- 2007-04-30 AR ARP070101874A patent/AR060732A1/es unknown
- 2007-04-30 MX MX2008013911A patent/MX2008013911A/es not_active Application Discontinuation
- 2007-04-30 CN CNA200780014675XA patent/CN101426494A/zh active Pending
- 2007-04-30 AU AU2007245983A patent/AU2007245983A1/en not_active Abandoned
- 2007-04-30 JP JP2009508134A patent/JP2009535367A/ja not_active Withdrawn
- 2007-04-30 BR BRPI0710230-5A patent/BRPI0710230A2/pt not_active IP Right Cessation
- 2007-04-30 EA EA200870491A patent/EA200870491A1/ru unknown
- 2007-04-30 WO PCT/DK2007/050050 patent/WO2007124757A2/fr not_active Ceased
- 2007-04-30 EP EP07722705A patent/EP2026793A2/fr not_active Withdrawn
- 2007-04-30 CA CA002651002A patent/CA2651002A1/fr not_active Abandoned
-
2008
- 2008-10-07 IL IL194628A patent/IL194628A0/en unknown
- 2008-10-09 ZA ZA2008/08632A patent/ZA200808632B/en unknown
- 2008-12-02 NO NO20085009A patent/NO20085009L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2651002A1 (fr) | 2007-11-08 |
| CN101426494A (zh) | 2009-05-06 |
| IL194628A0 (en) | 2009-08-03 |
| KR20090009820A (ko) | 2009-01-23 |
| AR060732A1 (es) | 2008-07-10 |
| TW200812993A (en) | 2008-03-16 |
| ZA200808632B (en) | 2009-12-30 |
| AU2007245983A1 (en) | 2007-11-08 |
| WO2007124757A3 (fr) | 2008-07-24 |
| JP2009535367A (ja) | 2009-10-01 |
| WO2007124757A2 (fr) | 2007-11-08 |
| EP2026793A2 (fr) | 2009-02-25 |
| BRPI0710230A2 (pt) | 2011-08-02 |
| EA200870491A1 (ru) | 2009-04-28 |
| NO20085009L (no) | 2008-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008013911A (es) | Uso de escitalopram para mejorar la capacidad de conocimiento. | |
| CN102512406B (zh) | 用于治疗认知障碍的α-氨基酰胺衍生物 | |
| US20070259952A1 (en) | Uses of escitalopram | |
| JP2020536901A5 (fr) | ||
| EA003142B1 (ru) | Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения | |
| EP3297619B1 (fr) | Utilisations thérapeutiques de la l-4-chlorocynurénine | |
| JP7429942B2 (ja) | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用 | |
| AU2010282509B2 (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions | |
| KR20170121333A (ko) | 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법 | |
| US20250179044A1 (en) | Methods of use of cyclic amide derivatives to treat schizophrenia | |
| EA006067B1 (ru) | Применение антагонистов 5-ht3 и нейрональных никотиновых рецепторов для лечения различных состояний | |
| JPH037218A (ja) | 薬剤組成物 | |
| EP1576985A1 (fr) | Utilisation d'antagonistes, d'agonistes partiels ou d'agonistes inverses des recepturs D4 et 5-HT2A | |
| US20230000799A1 (en) | Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy | |
| JP6084931B2 (ja) | ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン | |
| JPWO2004017973A1 (ja) | 統合失調症治療剤 | |
| HK1131337A (en) | Use of escitalopram for improving cognition | |
| CA2461248C (fr) | Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a | |
| CN112043700A (zh) | 盐酸去亚甲基四氢小檗碱在制备预防或治疗神经退行性疾病药物中的应用 | |
| US20210113494A1 (en) | Method Of Treating Post-Traumatic Stress Syndrome | |
| CN111743894A (zh) | 倍半萜内酯类化合物在制备治疗视神经炎药物上的应用 | |
| TWI417090B (zh) | 黃酮類化合物於治療伴有感覺運動門控缺損的精神異常疾病的用途 | |
| Capponi et al. | Diclofensine and imipramine: a double-blind comparative trial in depressive out-patients | |
| EP0876147A1 (fr) | Utilisation de galanthamine pour preparer de nouveaux medicaments | |
| HK40097673A (zh) | ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |